Literature DB >> 24827476

Morphine self-administration following spinal cord injury.

Sarah A Woller1, Jamal S Malik, Miriam Aceves, Michelle A Hook.   

Abstract

Neuropathic pain develops in up to two-thirds of people following spinal cord injury (SCI). Opioids are among the most effective treatments for this pain and are commonly prescribed. There is concern surrounding the use of these analgesics, however, because use is often associated with the development of addiction. Previous data suggests that this concern may not be relevant in the presence of neuropathic pain. Yet, despite the common prescription of opioids for the treatment of SCI-related pain, there has been only one previous study examining the addictive potential of morphine following spinal injury. To address this, the present study used a self-administration paradigm to examine the addictive potential of morphine in a rodent model of SCI. Animals were placed into self-administration chambers 24 h, 14 d, or 35 d following a moderate spinal contusion injury. They were placed into the chambers for seven 12-hour sessions with access to 1.5 mg morphine/lever depression (up to 30 mg/d). In the acute phase of SCI, contused animals self-administered significantly less morphine than their sham counterparts, as previously shown. However, contused animals showing signs of neuropathic pain did not self-administer less morphine than their sham counterparts when administration began 14 or 35 d after injury. Instead, these animals administered nearly the full amount of morphine available each session. This amount of morphine did not affect recovery of locomotor function but did cause significant weight loss. We suggest caution is warranted when prescribing opioids for the treatment of neuropathic pain resulting from SCI, as the addictive potential is not reduced in this model.

Entities:  

Keywords:  addiction; morphine; neuropathic pain; self-administration; spinal cord injury

Mesh:

Substances:

Year:  2014        PMID: 24827476      PMCID: PMC4161170          DOI: 10.1089/neu.2013.3293

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  80 in total

1.  Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission.

Authors:  Keiichi Niikura; Minoru Narita; Eduardo R Butelman; Mary Jeanne Kreek; Tsutomu Suzuki
Journal:  Trends Pharmacol Sci       Date:  2010-05-12       Impact factor: 14.819

Review 2.  Treatment of neuropathic pain: an overview of recent guidelines.

Authors:  Alec B O'Connor; Robert H Dworkin
Journal:  Am J Med       Date:  2009-10       Impact factor: 4.965

Review 3.  A systematic review of pharmacologic treatments of pain after spinal cord injury.

Authors:  Robert W Teasell; Swati Mehta; Jo-Anne L Aubut; Brianne Foulon; Dalton L Wolfe; Jane T C Hsieh; Andrea F Townson; Christine Short
Journal:  Arch Phys Med Rehabil       Date:  2010-05       Impact factor: 3.966

4.  Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity.

Authors:  Agnieszka Gieryk; Barbara Ziolkowska; Wojciech Solecki; Jakub Kubik; Ryszard Przewlocki
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

5.  The evidence for pharmacological treatment of neuropathic pain.

Authors:  Nanna Brix Finnerup; Søren Hein Sindrup; Troels Staehelin Jensen
Journal:  Pain       Date:  2010-09       Impact factor: 6.961

Review 6.  EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.

Authors:  N Attal; G Cruccu; R Baron; M Haanpää; P Hansson; T S Jensen; T Nurmikko
Journal:  Eur J Neurol       Date:  2010-04-09       Impact factor: 6.089

Review 7.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

8.  Changes in metabolic-related variables during chronic morphine treatment.

Authors:  Szilamér Ferenczi; Cristina Núñez; Bernadett Pintér-Kübler; Anna Földes; Fátima Martín; Vera Ladnyánszky Márkus; M Victoria Milanés; Krisztina J Kovács
Journal:  Neurochem Int       Date:  2010-06-26       Impact factor: 3.921

9.  Chronic neuropathic pain management in spinal cord injury patients. What is the efficacy of pharmacological treatments with a general mode of administration? (oral, transdermal, intravenous).

Authors:  N Attal; G Mazaltarine; B Perrouin-Verbe; T Albert
Journal:  Ann Phys Rehabil Med       Date:  2009-02-21

10.  Intrathecal morphine attenuates recovery of function after a spinal cord injury.

Authors:  Michelle A Hook; Georgina Moreno; Sarah Woller; Denise Puga; Kevin Hoy; Robyn Balden; James W Grau
Journal:  J Neurotrauma       Date:  2009-05       Impact factor: 5.269

View more
  6 in total

1.  Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

Authors:  Miriam Aceves; Eric A Bancroft; Alejandro R Aceves; Michelle A Hook
Journal:  J Neurotrauma       Date:  2016-11-04       Impact factor: 5.269

2.  Neurobiological Effects of Morphine after Spinal Cord Injury.

Authors:  Michelle A Hook; Sarah A Woller; Eric Bancroft; Miriam Aceves; Mary Katherine Funk; John Hartman; Sandra M Garraway
Journal:  J Neurotrauma       Date:  2016-11-02       Impact factor: 5.269

3.  Opioid prescription patterns among adults with cerebral palsy and spina bifida.

Authors:  Mark D Peterson; Neil Kamdar; Heidi J Haapala; Chad Brummett; Edward A Hurvitz
Journal:  Heliyon       Date:  2022-07-08

4.  Evaluation of the effects of specific opioid receptor agonists in a rodent model of spinal cord injury.

Authors:  M Aceves; B B Mathai; M A Hook
Journal:  Spinal Cord       Date:  2016-03-01       Impact factor: 2.772

5.  Effects of combination treatment with transcranial magnetic stimulation and bone marrow mesenchymal stem cell transplantation or Raf inhibition on spinal cord injury in rats.

Authors:  Sining Feng; Shuai Wang; Shi Sun; Hao Su; Lixin Zhang
Journal:  Mol Med Rep       Date:  2021-03-02       Impact factor: 2.952

6.  Morphine-induced changes in the function of microglia and macrophages after acute spinal cord injury.

Authors:  Mabel N Terminel; Carla Bassil; Josephina Rau; Amanda Trevino; Cristina Ruiz; Robert Alaniz; Michelle A Hook
Journal:  BMC Neurosci       Date:  2022-10-10       Impact factor: 3.264

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.